{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:34:44Z","timestamp":1782538484555,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03144-4","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:06:20Z","timestamp":1745489180000},"page":"2690-2707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent\/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-3282","authenticated-orcid":false,"given":"Marcin","family":"Dzienis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-8627","authenticated-orcid":false,"given":"Ali","family":"Mojebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-1536","authenticated-orcid":false,"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-108X","authenticated-orcid":false,"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Giezek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroshini","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3741-6208","authenticated-orcid":false,"given":"Chiara","family":"Vanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-5443","authenticated-orcid":false,"given":"Julie E.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-4036","authenticated-orcid":false,"given":"Dandan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"6","key":"3144_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3144_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels JP, Ren\u00e9 Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.011.","journal-title":"Ann Oncol"},{"issue":"7","key":"3144_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1080\/0284186x.2021.1925343","volume":"60","author":"D Borsetto","year":"2021","unstructured":"Borsetto D, Sethi M, Polesel J, et al. The risk of recurrence in surgically treated head and neck squamous cell carcinomas: a conditional probability approach. Acta Oncol. 2021;60(7):942\u20137. https:\/\/doi.org\/10.1080\/0284186x.2021.1925343.","journal-title":"Acta Oncol"},{"issue":"10_suppl","key":"3144_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1200\/OP.2024.20.10_suppl.375","volume":"20","author":"D Zheng","year":"2024","unstructured":"Zheng D, Zhang S, Bidadi B, et al. Real-world event-free survival (rwEFS) and overall survival (rwOS) in elderly patients with resected locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US. JCO Oncol Pract. 2024;20(10_suppl):375. https:\/\/doi.org\/10.1200\/OP.2024.20.10_suppl.375.","journal-title":"JCO Oncol Pract."},{"issue":"1","key":"3144_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40463-017-0199-x","volume":"46","author":"E Winquist","year":"2017","unstructured":"Winquist E, Agbassi C, Meyers BM, Yoo J, Chan KKW. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. J Otolaryngol Head Neck Surg. 2017;46(1):29. https:\/\/doi.org\/10.1186\/s40463-017-0199-x.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"3144_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100375","volume":"27","author":"F Pontes","year":"2021","unstructured":"Pontes F, Garcia AR, Domingues I, et al. Survival predictors and outcomes of patients with recurrent and\/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: a real-world retrospective study. Cancer Treat Res Commun. 2021;27: 100375. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100375.","journal-title":"Cancer Treat Res Commun"},{"key":"3144_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"issue":"11","key":"3144_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med"},{"issue":"5","key":"3144_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s12094-020-02533-1","volume":"23","author":"R Mesia","year":"2021","unstructured":"Mesia R, Iglesias L, Lambea J, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol. 2021;23(5):913\u201321. https:\/\/doi.org\/10.1007\/s12094-020-02533-1.","journal-title":"Clin Transl Oncol"},{"key":"3144_CR10","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Head and Neck Cancers V.5.2024.: \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [October 28, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed."},{"key":"3144_CR11","unstructured":"Cancer Institute NSW: Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin PACLitaxel and pembrolizumab INTERIM. https:\/\/www.eviq.org.au\/medical-oncology\/head-and-neck\/recurrent-or-metastatic\/4363-head-and-neck-scc-recurrent-or-metastatic-car Accessed June 18 2024."},{"key":"3144_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02625","author":"M Dzienis","year":"2024","unstructured":"Dzienis M, Cundom J, Fuentes CS, et al. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/jco.23.02625.","journal-title":"J Clin Oncol"},{"key":"3144_CR13","first-page":"267","volume-title":"Critical issues in head and neck oncology: key concepts from the sixth THNO meeting","author":"J Guigay","year":"2018","unstructured":"Guigay J. Are there alternative chemotherapy regimens for EXTREME in recurrent\/metastatic squamous cell carcinoma of the head and neck (R\/M-SCCHN)? In: Vermorken JB, Budach V, Leemans CR, Machiels J-P, Nicolai P, O\u2019Sullivan B, editors. Critical issues in head and neck oncology: key concepts from the sixth THNO meeting. Cham: Springer; 2018. p. 267\u201376."},{"key":"3144_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3389\/fonc.2019.00668","volume":"9","author":"J Guigay","year":"2019","unstructured":"Guigay J, Tahara M, Licitra L, et al. The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions. Front Oncol. 2019;9:668. https:\/\/doi.org\/10.3389\/fonc.2019.00668.","journal-title":"Front Oncol"},{"issue":"1","key":"3144_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21115\/JBES.v16.n1.p25-64","volume":"16","author":"A Mojebi","year":"2024","unstructured":"Mojebi A, Ramakrishnan K, Ayers D, Keeping S, Borse R, Chirovsky D. Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. J Bras Econ Sa\u00fade. 2024;16(1):25\u201364. https:\/\/doi.org\/10.21115\/JBES.v16.n1.p25-64.","journal-title":"J Bras Econ Sa\u00fade"},{"issue":"15_suppl","key":"3144_CR16","doi-asserted-by":"publisher","first-page":"e18012-e","DOI":"10.1200\/JCO.2021.39.15_suppl.e18012","volume":"39","author":"K Ramakrishnan","year":"2021","unstructured":"Ramakrishnan K, Mojebi A, Ayers D, Chirovsky DR, Borse R, Keeping S. Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2021;39(15_suppl):e18012-e. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e18012.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3144_CR17","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0098","volume":"12","author":"R Hanvesakul","year":"2023","unstructured":"Hanvesakul R, Rengarajan B, Naveh N, et al. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. J Comp Eff Res. 2023;12(5): e220098. https:\/\/doi.org\/10.57264\/cer-2022-0098.","journal-title":"J Comp Eff Res"},{"key":"3144_CR18","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016. http:\/\/www.nicedsu.org.uk."},{"issue":"9","key":"3144_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.oraloncology.2013.05.010","volume":"49","author":"A D'Cruz","year":"2013","unstructured":"D\u2019Cruz A, Lin T, Anand AK, et al. Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. Oral Oncol. 2013;49(9):872\u20137. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.05.010. (Epub Jul 4).","journal-title":"Oral Oncol"},{"key":"3144_CR20","unstructured":"Gilbert R, Devries-Aboud M, Winquist E, Waldron J, McQuestion M, Head and Neck Disease Site Group. The management of head and neck cancer in Ontario. Toronto (ON): Cancer Care Ontario; 2009 Dec 15 [In review 2015 Nov]. Program in Evidence-based Care Evidence-Based Series No.:5\u20133 IN REVIEW. 2015."},{"issue":"6","key":"3144_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.oraloncology.2013.01.005","volume":"49","author":"F Peyrade","year":"2013","unstructured":"Peyrade F, Cupissol D, Geoffrois L, et al. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol. 2013;49(6):482\u201391. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.01.005. (Epub Feb 13).","journal-title":"Oral Oncol"},{"key":"3144_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3144_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"28","key":"3144_CR24","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"issue":"10","key":"3144_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345. https:\/\/doi.org\/10.2165\/11538370-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"3144_CR26","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. 2011; last updated September 2016. http:\/\/www.nicedsu.org.uk."},{"key":"3144_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"3144_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515\u201326.","journal-title":"Biometrika"},{"issue":"1","key":"3144_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341.","journal-title":"Biometrika"},{"issue":"1","key":"3144_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-11-61","volume":"11","author":"JP Jansen","year":"2011","unstructured":"Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11(1):61. https:\/\/doi.org\/10.1186\/1471-2288-11-61.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"3144_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-12-152","volume":"12","author":"JP Jansen","year":"2012","unstructured":"Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12(1):152. https:\/\/doi.org\/10.1186\/1471-2288-12-152.","journal-title":"BMC Med Res Methodol"},{"issue":"3\u20134","key":"3144_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jrsm.25","volume":"1","author":"MJ Ouwens","year":"2010","unstructured":"Ouwens MJ, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010;1(3\u20134):258\u201371. https:\/\/doi.org\/10.1002\/jrsm.25.","journal-title":"Res Synth Methods"},{"issue":"8","key":"3144_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"AA Forastiere","year":"1992","unstructured":"Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245\u201351.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3144_CR34","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","volume":"23","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3144_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"J Guigay","year":"2021","unstructured":"Guigay J, Auperin A, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(20)30755-5.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3144_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257\u201363.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"3144_CR37","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1200\/jco.2014.32.15_suppl.6021","volume":"32","author":"JB Vermorken","year":"2014","unstructured":"Vermorken JB, Remenar E, Hitt R, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R\/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol. 2014;32(15_suppl):6021. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.6021.","journal-title":"J Clin Oncol"},{"key":"3144_CR38","doi-asserted-by":"publisher","first-page":"S839","DOI":"10.1016\/j.annonc.2022.07.775","volume":"33","author":"M Dzienis","year":"2022","unstructured":"Dzienis M, Cundom J, Fuentes C, et al. 651O Pembrolizumab (pembro)+ carboplatin (carbo)+ paclitaxel (pacli) as first-line (1L) therapy in recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): phase VI KEYNOTE-B10 study. Ann Oncol. 2022;33:S839\u201340.","journal-title":"Ann Oncol"},{"issue":"6","key":"3144_CR39","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1016\/j.jval.2024.03.1848","volume":"27","author":"A Mojebi","year":"2024","unstructured":"Mojebi A, Zheng D, Park J, et al. SA1 methods for incorporating non-randomized evidence from single-arm trials into network meta-analysis (NMA): a case study in recurrent\/metastatic head and neck cancer (R\/M-HNSCC). Value in Health. 2024;27(6):S396. https:\/\/doi.org\/10.1016\/j.jval.2024.03.1848.","journal-title":"Value in Health"},{"issue":"5","key":"3144_CR40","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.ijrobp.2024.01.076","volume":"118","author":"D Zheng","year":"2024","unstructured":"Zheng D, Black CM, Mojebi A, Keeping S, Park JE. Comparative efficacy of KEYNOTE-B10 regimen as first-line (1L) therapy in recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): a network meta-analysis (NMA) with aggregate-level matching. Int J Radiat Oncol Biol Phys. 2024;118(5):e32\u20133. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.076.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3144_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/s0266462319000333","volume":"35","author":"D Phillippo","year":"2019","unstructured":"Phillippo D, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence Technology Appraisals. Int J Technol Assess Health Care. 2019;35(3):221\u20138. https:\/\/doi.org\/10.1017\/s0266462319000333.","journal-title":"Int J Technol Assess Health Care"},{"key":"3144_CR42","doi-asserted-by":"publisher","first-page":"1348045","DOI":"10.3389\/fonc.2024.1348045","volume":"14","author":"CM Black","year":"2024","unstructured":"Black CM, Zheng D, Hair GM, et al. Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent \/ metastatic head and neck squamous cell carcinoma. Front Oncol. 2024;14:1348045. https:\/\/doi.org\/10.3389\/fonc.2024.1348045.","journal-title":"Front Oncol"},{"key":"3144_CR43","doi-asserted-by":"publisher","first-page":"1160144","DOI":"10.3389\/fonc.2023.1160144","volume":"13","author":"CM Black","year":"2023","unstructured":"Black CM, Hanna GJ, Wang L, et al. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent\/metastatic head and neck squamous cell carcinoma. Front Oncol. 2023;13:1160144. https:\/\/doi.org\/10.3389\/fonc.2023.1160144.","journal-title":"Front Oncol"},{"key":"3144_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106997","volume":"158","author":"L Sun","year":"2024","unstructured":"Sun L, Cohen RB, Dimitrios CA. Platinum\/taxane\/pembrolizumab vs platinum\/5FU\/pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma (r\/m HNSCC). Oral Oncol. 2024;158: 106997. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106997.","journal-title":"Oral Oncol"},{"issue":"3","key":"3144_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03144-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03144-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03144-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:00:40Z","timestamp":1747468840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03144-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3144"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03144-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marcin Dzienis declares a consultant or advisory role with MSD, Bristol-Myers Squibb, and Novartis and has received payment or honoraria for presentations and serving as a speaker from MSD, Novartis, AstraZeneca, and Bristol-Myers Squibb, and for education support from Pierre Fabre and MSD. Christopher M. Black, Sanjay Merchant, and Dandan Zheng are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and are shareholders in Merck & Co., Inc., Rahway, NJ, USA. Hilde Giezek and Chiara Vanetta are employees of MSD subsidiaries of Merck & Co., Inc., Rahway, NJ, USA. Niroshini Naicker is an employee of an MSD subsidiary of Merck & Co., Inc., Rahway, NJ, USA and is a shareholder in Merck & Co., Inc., Rahway, NJ, USA. Ali Mojebi, Sam Keeping, Julie E. Park, and Keith Chan are employed by the company Precision AQ, which received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}